Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study

作者：Yuankai Shi, Yanzhen Guo, Xingya Li, Lin Wu, Zhaohong Chen, Sheng Yang, Minghong Bi, Yanqiu Zhao, Wenxiu Yao, Huiqing Yu, Ke Wang, Wenhua Zhao, Meili Sun, Liangming Zhang, Zhiyong He, Yingcheng Lin, Jianhua Shi, Bo Zhu, Lijun Wang, Yueyin Pan, Huaqiu Shi, Shenghua Sun, Meiling Wen, Rui Zhou, Shuliang Guo, Zhigang Han, Tienan Yi, Hua Zhang, Shundong Cang, Zhuang Yu, Diansheng Zhong, Jiuwei Cui, Jian Fang, Jinghua Gao, Manxiang Li, Rui Ma, Mingyan Jiang, Jianwen Qin, Yongqian Shu, Feng Ye, Sheng Hu, Wen Li, Hong Lü, Minglei Yang, Shanyong Yi, Yan Zhang, Yun Fan, Hongbo Ji, Zheng Liu, Haitao Wang, Xiangdong Zhou, Don C. Zhang, Jirong Peng, Haijiao Shen, Feng Gao, Tingting Wang, Anqi Zhou · 发表于：The Lancet Respiratory Medicine · 年份：2025 · DOI：10.1016/s2213-2600(24)00417-x · 被引用次数：16 · 研究领域：Lung Cancer Treatments and Mutations、Cancer Immunotherapy and Biomarkers、Lung Cancer Research Studies